Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple scan reveal why muscles tire in phosphate diabetes?

NCT ID NCT06921720

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study uses a special MRI technique to measure energy molecules (ATP and phosphate) in the leg muscles of people with phosphate diabetes, a condition that causes bone pain and muscle fatigue. By comparing measurements at rest and during exercise, researchers hope to uncover the link between low phosphate levels and muscle weakness. The goal is to find objective markers of muscle health that could improve understanding of the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide objective biomarkers to assess muscle metabolism in phosphate diabetes, potentially guiding future treatments.
What could go wrong
This is an observational study with no intervention, so it cannot directly improve outcomes. The findings may not translate into clinical benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 65 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion Criteria for Patients: * Patient ≥ 10 years old with phosphate diabetes, i.e., genetically confirmed XLH or phosphate diabetes of another origin characterized by hypophosphatemia with a decreased Tm/GFR. * Patient has given consent to participate in the study. * Signed consent (by both legal representatives for minor patients). * Patient regularly followed up within the pediatric nephrology services at the Femme Mère Enfant hospital and the nephrology-functional exploration services at the Edouard Herriot hospital. Inclusion Criteria for Pediatric Controls: * Patient aged 10 to 17 years, without chronic kidney disease, without hypophosphatemia, without muscular abnormalities, and without growth disorders. * Patient has given consent to participate in the study. * Signed consent (by both legal representatives for minor patients). * Patient regularly followed up within the pediatric nephrology services at the Femme Mère Enfant hospital. Inclusion Criteria for Adult Controls: * Patient without chronic kidney disease, without hypophosphatemia, without muscular abnormalities, and without malnutrition. * Patient has given consent to participate in the study. * Signed consent. * Patient regularly followed up within the renal functional exploration services at the Edouard Herriot hospital. Exclusion Criteria: * Pregnant, parturient, or breastfeeding women * Individuals deprived of liberty by a judicial or administrative decision * Individuals receiving psychiatric care * Individuals admitted to a healthcare or social institution for purposes other than research * Adults under legal protection (guardianship, curators) * Individuals not affiliated with a social security system or benefiting from a similar scheme * Subjects participating in another interventional study with an exclusion period still in effect at pre-inclusion * General contraindications for MRI: wearing a pacemaker/ICD (implantable cardiac device) or mechanical heart valves not MRI-compatible, presence of non-MRI-compatible equipment, presence of metallic objects.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Phosphate diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypophosphatemia Hypophosphatemia, Familial X-linked dominant hypophosphatemic rickets X-linked hypophosphatemic rickets

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Phosphate diabetes X-linked hypophosphatemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Edouard Herriot, Hospices Civils de Lyon

    RECRUITING

    Lyon, 69003, France

  • Hôpital femme mère enfant, hospices civils de Lyon

    NOT_YET_RECRUITING

    Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.